HDFC MF and ADIA Lead ₹777 Crore Block Deal in Corona Remedies
A significant shift in the ownership structure of pharmaceutical player Corona Remedies Limited occurred on June 17, 2026, as major institutional investors stepped in to acquire a substantial stake. This massive block deal marks a key movement in the healthcare sector, involving some of the world’s most prominent asset management firms.
Massive Divestment by Sepia Investments and Anchor Partners
The block deal was headlined by Sepia Investments, which offloaded 43,28,943 shares of Corona Remedies. Executed at a price of ₹1,730 per share, the transaction by Sepia alone amounted to approximately ₹748.9 crore. Adding to the sell-side momentum, Anchor Partners also divested its holdings, selling 1,61,861 shares at the same price point, worth roughly ₹28 crore.
In total, these two sellers successfully exited or reduced their positions by offloading shares worth approximately ₹776.9 crore in the pharmaceutical company, signaling a major liquidity event in the stock.
HDFC Mutual Fund Dominates the Buy Side
While the sell-side was concentrated among two entities, the buy-side saw intense participation from twelve different institutional investors. HDFC Mutual Fund emerged as the most aggressive buyer, single-handedly absorbing more than half of the total deal value. HDFC MF acquired 24,50,000 shares, an investment totaling roughly ₹423.9 crore.
Other heavyweight domestic and international players also secured significant positions:
- Aditya Birla Sun Life Mutual Fund: Purchased 4,90,000 shares worth ₹84.8 crore.
- Aberdeen Asian Smaller Companies Investment Trust Plc: Bought 4,50,868 shares valued at ₹78 crore.
- Invesco Mutual Fund: Acquired 2,89,017 shares for approximately ₹50 crore.
- Kotak Mahindra Mutual Fund: Picked up 1,61,861 shares worth ₹28 crore, a volume that exactly matched the quantity sold by Anchor Partners.
Global Institutional Interest in Corona Remedies
The deal also highlights growing interest from global sovereign wealth funds and specialized emerging market funds. The Abu Dhabi Investment Authority (ADIA) participated in the deal, purchasing 39,130 shares worth approximately ₹6.8 crore.
さらに、WhiteOakグループは強い確信を示しており、Ashoka WhiteOak Emerging Markets Equity Fundが148,686株（2.57億ルピー）を購入し、WhiteOak Capital Mutual Fundが145,000株（2.51億ルピー）を取得しました。その他の参加者には、Aberdeen Standard Sicav I、India Acorn ICAV、Factory Mutual Insurance Companyなどが含まれており、1,730ルピーという価格水準における同社への広範な機関投資家の信頼を裏付けています。
主なポイント
- 大規模な持ち分譲渡: Sepia InvestmentsとAnchor Partnersは、ブロック取引を通じてCorona Remediesの持ち分を合計約77.69億ルピー売却しました。
- 主要買い手としてのHDFC MF: HDFC Mutual Fundが主要な取得者となり、245万株に対して42.39億ルピーを投資しました。これは取引額の50%以上を占めています。
- 広範な機関投資家の意欲: この取引には、ADIAやAberdeenといったグローバル大手からインドの主要な投資信託まで、12の多様な投資家グループが参加しました。